Flare Therapeutics

Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer

– Proceeds will fund advancement of ARON degrader, FX-111, to proof of concept and preclinical development of ARON RIPTAC program – Veteran biotech executive, Anna Protopapas, appointed as CEO to guide company through next phase of growth focused on prostate cancer Cambridge, MA, June 30, 2026 —…

Flare Therapeutics Announces Three Upcoming Poster Presentations at AACR Annual Meeting 2026

Cambridge, MA, April 6, 2026 — Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that it will present three posters at the upcoming American Association…

Flare Therapeutics Presents Updated FX-909 Phase 1A Data in Late-Breaking Oral Presentation at 2026 ASCO Genitourinary Cancers Symposium

– Data support emergence of differentiating clinical benefit with a favorable safety and tolerability profile for patients with advanced UC Cambridge, MA, Feb. 27, 2026 — Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision…

Flare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer

Cambridge, MA, January 9, 2026 — Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced the appointment of Stephen L. Eck, M.D., Ph.D., as Chief Medical…

Flare Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Cambridge, MA, Jan. 8, 2026 — Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that Doug Manion, M.D., FRCP (C), Chief Executive Officer and Board…

Flare Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

Cambridge, MA, Nov. 25, 2025 — Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that Douglas Manion, M.D., FRCP (C), Chief Executive Officer, will…